Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

Novo­cure has se­cured the FDA’s bless­ing for an­oth­er use of its tu­mor treat­ing fields: ma­lig­nant pleur­al mesothe­lioma, a rare can­cer that de­vel­ops in the lin­ings of the lung and chest.

The NovoT­TF-100L Sys­tem is to be de­ployed with Eli Lil­ly’s Al­im­ta (peme­trexed) and a plat­inum-based chemother­a­py in the first-line treat­ment of un­re­sectable, lo­cal­ly ad­vanced or metasta­t­ic forms of the dis­ease. Cur­rent­ly, on­ly 10% to 20% of MPM pa­tients are can­di­dates for surgery to re­move the tu­mor, ac­cord­ing to Mary Hes­dorf­fer of the Mesothe­lioma Ap­plied Re­search Foun­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.